BioCentury | Aug 25, 2020

Reverse merger offers Yumanity faster, less risky path to NASDAQ

Despite continued demand for biotech IPOs, Yumanity has opted to take a less traditional route to the public markets in a move that it views as more efficient and less risky.  On Monday, the company...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jul 10, 2020

How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...
BioCentury | Jun 30, 2020
Product Development

Vertex, NHS in deal to make CF triplet available in England once EC approves

It took four years for Vertex to reach an agreement with England’s NHS for access to its first combination cystic fibrosis therapy. But there won’t be any wait for the biotech’s highly anticipated triple therapy...
BioCentury | Jun 26, 2020

Data Bytes: CHMP’s June opinions

A recommendation by EMA’s CHMP suggests remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) could soon gain a speedy conditional approval to treat COVID-19. The committee announced the decision this week along with a basket of other...
BioCentury | May 25, 2020

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of...
BioCentury | Apr 30, 2020

April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent

Immunomedics raises $420M to roll out Trodelvy for breast cancer Immunomedics Inc. (NASDAQ:IMMU) raised $420 million late Tuesday through the sale of 14.7 million shares at $28.50 in a bumped-up follow-on. The price is a...
BioCentury | Apr 4, 2020

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...$180 million through the sale of 7.8 million shares at $23; and deuterium chemistry company Concert Pharmaceuticals...
...Editor Paul Bonanos, Associate Editor and Elizabeth S. Eaton, Staff Writer Biohaven Pharmaceutical Holding Co. Ltd. Denali Therapeutics Inc. Concert Pharmaceuticals...
Items per page:
1 - 10 of 514